Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients With Type 2 Diabetes

Beyond improving hemoglobin A1c (HbA1c) in adults with type 2 diabetes, glucagon-like peptide 1 receptor agonists (GLP-1RA) have been approved for reducing risk of major adverse cardiovascular events (MACE) with established cardiovascular disease (CVD) or multiple CV risk factors. Sodium-glucose cot...

Descripción completa

Detalles Bibliográficos
Autores principales: Yanai, Hidekatsu, Adachi, Hiroki, Hakoshima, Mariko, Katsuyama, Hisayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990545/
https://www.ncbi.nlm.nih.gov/pubmed/36896226
http://dx.doi.org/10.14740/cr1459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990545/
https://www.ncbi.nlm.nih.gov/pubmed/36896226
http://dx.doi.org/10.14740/cr1459

Ejemplares similares